| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.45 M USD | 1.17 M USD | -23.08 M USD | 9.36 M USD | -142.69 M USD | -159.47 M USD | -165.70 M USD | -106.81 M USD | -76.16 M USD | -69.14 M USD | -79.04 M USD | -45.52 M USD |
| Depreciation & Amortization | 384000 USD | 509000 USD | 922000 USD | 1.19 M USD | 4.09 M USD | 1.04 M USD | 612786 USD | 293886 USD | 213117 USD | 132451 USD | 62400 USD | 52467 USD |
| Stock-Based Compensation | 75000 USD | 264000 USD | 1.27 M USD | 11.57 M USD | 18.13 M USD | 10.68 M USD | 10.69 M USD | 8.66 M USD | 6.89 M USD | 17.41 M USD | 7.19 M USD | 4.24 M USD |
| Capital Expenditures | — | — | — | — | 34000 USD | 207073 USD | 2.45 M USD | 217040 USD | 61817 USD | 396154 USD | 165257 USD | 30962 USD |
| Cash Flow from Investing | — | — | — | -355000 USD | -2.22 M USD | -1.60 M USD | -23.91 M USD | -21.50 M USD | -827108 USD | -1.26 M USD | -584361 USD | -606756 USD |
| Cash Flow from Financing | — | — | 3.15 M USD | -235.21 M USD | 129.55 M USD | 80.72 M USD | 188.83 M USD | 162.79 M USD | 72.58 M USD | 137.23 M USD | 92.97 M USD | 43.30 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | -142.73 M USD | -159.68 M USD | -168.15 M USD | -107.03 M USD | -76.22 M USD | -69.54 M USD | -79.21 M USD | -45.55 M USD |
TherapeuticsMD, Inc. is a specialty pharmaceutical and royalty company focused on women’s health in the United States and internationally. The company’s primary role is to develop and license differentiated therapies that address conditions associated with menopause, contraception, and related gynecologic needs. Through licensing agreements, TherapeuticsMD grants commercial rights to partners such as Mayne Pharma for products including hormone therapy and contraceptive offerings, while retaining economic interests via royalties. Its portfolio is complemented by vitamin and prenatal brands historically developed through its VitaMed business, aimed at obstetric and gynecologic practices. By concentrating on proprietary formulations and lifecycle management rather than large-scale sales infrastructure, TherapeuticsMD, Inc. positions itself as an asset-light participant in the pharmaceutical value chain, contributing specialized products to the broader women’s healthcare market.